Stryker (SYK) Projected to Post Quarterly Earnings on Thursday

Stryker (NYSE:SYK) is anticipated to issue its Q4 2025 results after the market closes on Thursday, January 29th. Analysts expect Stryker to post earnings of $4.39 per share and revenue of $7.1205 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, January 29, 2026 at 4:30 PM ET.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Friday, October 31st. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The firm had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.87 earnings per share. On average, analysts expect Stryker to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Stryker Stock Up 0.9%

Stryker stock opened at $362.75 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. The stock has a market capitalization of $138.72 billion, a PE ratio of 47.67, a price-to-earnings-growth ratio of 2.30 and a beta of 0.89. The business has a 50 day simple moving average of $360.21 and a 200-day simple moving average of $373.29. Stryker has a 12 month low of $329.16 and a 12 month high of $406.19.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be given a dividend of $0.88 per share. The ex-dividend date is Wednesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is presently 46.25%.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Raymond James Financial upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price objective for the company in a report on Tuesday, January 6th. UBS Group set a $408.00 price target on Stryker in a research report on Monday, October 13th. Barclays increased their price target on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Truist Financial lowered their price objective on Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. Finally, Sanford C. Bernstein upped their target price on Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a report on Friday, January 9th. Fourteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $430.00.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the transaction, the chief financial officer owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. This trade represents a 2.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 522,118 shares of company stock valued at $185,381,932 in the last ninety days. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Stryker

Hedge funds have recently bought and sold shares of the stock. Tcfg Wealth Management LLC grew its position in shares of Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after buying an additional 29 shares in the last quarter. CYBER HORNET ETFs LLC lifted its stake in Stryker by 3.3% in the third quarter. CYBER HORNET ETFs LLC now owns 931 shares of the medical technology company’s stock worth $344,000 after acquiring an additional 30 shares during the last quarter. Sompo Asset Management Co. Ltd. grew its holdings in Stryker by 1.3% during the 2nd quarter. Sompo Asset Management Co. Ltd. now owns 2,390 shares of the medical technology company’s stock worth $946,000 after acquiring an additional 30 shares in the last quarter. Sittner & Nelson LLC increased its position in shares of Stryker by 0.3% in the 3rd quarter. Sittner & Nelson LLC now owns 11,770 shares of the medical technology company’s stock valued at $4,351,000 after purchasing an additional 35 shares during the last quarter. Finally, Binnacle Investments Inc raised its holdings in shares of Stryker by 26.1% in the 2nd quarter. Binnacle Investments Inc now owns 179 shares of the medical technology company’s stock valued at $71,000 after purchasing an additional 37 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.